Significant activities have centered around Regeneron Pharmaceuticals, Inc. (REGN) lately. The company acquired 23andMe assets for $256M and a positive focus on its product Dupixent is being indicated as a potential offset to Eylea's declining market share. Several investment firms, including Lifeworks Advisors, Longleaf Partners Fund, Pacer Advisors, Morse Asset Management, and Edgestream Partners have shown confidence by increasing their stake, while others such as Bank of America Securities and UBS lowered their price targets. Nonetheless, JP Morgan called recent sell-off excessive and retains a $800 price target. Regeneron also made headlines for winning FDA approval for Dupixent and announcing $50K Regeneron Prizes to MIT and Harvard scientists for groundbreaking medical research ideas. Their product Lynozyfic gained an accelerated FDA approval for multiple myeloma treatment. Although their GLP-1/GIP drug rights secured a $80 million deal, concerns rise due to surprises like the Sanofi-tied failure which affected the stock negatively.
Regeneron Pharmaceuticals REGN News Analytics from Wed, 02 Apr 2025 07:00:00 GMT to Sat, 26 Jul 2025 11:18:21 GMT - Rating 4 - Innovation 6 - Information 8 - Rumor -6
